Kanagawa, Japan

Takeshi Wakabayashi

USPTO Granted Patents = 10 

 

Average Co-Inventor Count = 8.4

ph-index = 2

Forward Citations = 13(Granted Patents)


Location History:

  • Guilderland, NY (US) (2012)
  • Kanagawa, JP (2015 - 2023)
  • Fujisawa, JP (2020 - 2024)

Company Filing History:


Years Active: 2012-2025

Loading Chart...
Loading Chart...
10 patents (USPTO):

Title: The Innovations of Takeshi Wakabayashi: Pioneering Heterocyclic Compounds

Introduction: Takeshi Wakabayashi, an influential inventor based in Kanagawa, Japan, has made significant contributions to the field of pharmaceutical innovation. With a substantial portfolio that boasts nine patents, Wakabayashi is recognized for his pioneering work in developing novel heterocyclic compounds that address critical health issues.

Latest Patents: Among Wakabayashi's most recent patents are compounds designed to target the N-methyl-D-aspartate (NMDA) receptor containing the NR2B subunit. His inventions hold the potential to serve as prophylactic or therapeutic agents for a variety of conditions, including depression, bipolar disorder, migraine, pain, and peripheral symptoms of dementia. His detailed patents encompass compounds represented by a specific formula, indicating each symbol’s definition as outlined in the patent's description, as well as potential salts of these compounds.

Career Highlights: Currently, Wakabayashi is associated with Takeda Pharmaceutical Company Limited, a leading entity in the pharmaceutical industry. His work is a testament to his commitment to advancing medical research and finding innovative solutions to complex health challenges.

Collaborations: Throughout his career, Wakabayashi has collaborated with notable colleagues, including Yuya Oguro and Shigemitsu Matsumoto. Their combined efforts have propelled advancements in the understanding and application of heterocyclic compounds within therapeutic contexts.

Conclusion: Takeshi Wakabayashi stands out as a remarkable inventor whose contributions are shaping the future of medicine. His dedicated research at Takeda Pharmaceutical Company Limited and his valuable patents demonstrate a commitment to improving healthcare outcomes through innovation. As he continues to explore the potential of heterocyclic compounds, the impact of his work is expected to resonate in the field of pharmacology for years to come.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…